Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Frequently asked questions
What sector does Oncolytics Biotech Inc (ONC) operate in?
Oncolytics Biotech Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Oncolytics Biotech Inc (ONC) current stock price?
As of the latest data, Oncolytics Biotech Inc stock price is CA$1.42, with a previous close of CA$1.39. Oncolytics Biotech Inc gained CA$0.03 in the last trading session, representing a 2.16% increase.
What is Oncolytics Biotech Inc (ONC) current market capitalization?
Oncolytics Biotech Inc market cap is approximately 142.51 million.
What is Oncolytics Biotech Inc (ONC) Earnings Per Share (EPS)?
The trailing EPS is -CA$0.37, and the forward EPS is -CA$0.33.
Does Oncolytics Biotech Inc (ONC) pay dividends?
No. Oncolytics Biotech Inc does not pay a dividend.
What is Oncolytics Biotech Inc (ONC) beta (volatility) score?
Oncolytics Biotech Inc has a beta of 1.475, suggesting it is more volatile than the market.